Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Investigation launched into Wise Group over alleged misleading info amid money laundering probe

Market News
03 Jun 2026
PRNewsWire
View Source
Bearish
pluang ai news

Rosen Law Firm has announced an investigation into Wise Group plc following allegations that the company issued misleading business information related to a money laundering probe reported by The Wall Street Journal. The news caused Wise's stock to drop sharply on June 1, 2026. Investors who purchased Wise securities may join a class action lawsuit seeking compensation without upfront fees. The Rosen Law Firm, experienced in securities litigation, is leading the case to recover investor losses.

More News

Vistra Corp. sees strong Q1 growth and bullish outlook on power deals with tech giants.

Vistra Corp. sees strong Q1 growth and bullish outlook on power deals with tech giants.

Vistra Corp. reported a 20% year-over-year increase in adjusted EBITDA for Q1 2026, driven by improved energy margins and acquisitions. Revenue rose to $5.63 billion with a 26.6% operating margin. The company benefits from long-term power purchase ag...

Analyst Insights
Bullish
4 hours ago
CoreWeave Q1 revenue soars 112% YoY with backlog hitting $99.4B amid strong AI demand

CoreWeave Q1 revenue soars 112% YoY with backlog hitting $99.4B amid strong AI demand

CoreWeave reported a 112% year-over-year revenue increase in Q1 and a 284% surge in backlog to $99.4 billion, driven by strong demand in AI and tech sectors. Despite some margin pressure due to aggressive expansion and capital expenditures, the compa...

Analyst Insights
Bullish
4 hours ago
Nipocalimab shows sustained reduction in lupus disease activity through 52 weeks in Phase 2 trial.

Nipocalimab shows sustained reduction in lupus disease activity through 52 weeks in Phase 2 trial.

Johnson & Johnson's nipocalimab, a novel FcRn blocker, met its primary endpoint by significantly reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) at 24 weeks, with benefits sustained through 52 weeks in a...

Company Fundamentals
Bullish
4 hours ago
Nipocalimab shows strong clinical response in Sjögren's disease patients with high autoantibody levels in Phase 2 trial.

Nipocalimab shows strong clinical response in Sjögren's disease patients with high autoantibody levels in Phase 2 trial.

Johnson & Johnson announced new Phase 2 data for nipocalimab, an immunoselective FcRn blocker, showing greater clinical response in Sjögren's disease patients with elevated autoantibodies and IgG levels. The drug reduced disease activity and symptoms...

Company Fundamentals
Bullish
4 hours ago
SEALSQ leads €130M Series A round in Quobly to boost secure quantum computing tech in Europe

SEALSQ leads €130M Series A round in Quobly to boost secure quantum computing tech in Europe

SEALSQ has led a €130 million Series A funding round for Quobly, a company developing silicon-based quantum processors, to accelerate industrial deployment of secure quantum computing systems. This investment, made via SEALSQ's Quantum Fund, strength...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App